We are the Sumocat of four worlds: Lemmy, Mastodon, Photofed, and Calckey.

  • 1 Post
  • 138 Comments
Joined 3 years ago
cake
Cake day: July 4th, 2023

help-circle





  • Sumocat@lemmy.worldtoFunny@sh.itjust.worksCatch 22
    link
    fedilink
    English
    arrow-up
    7
    ·
    11 days ago

    In single-blind peer review, it’s just the reviewer. In double-blind, it’s both reviewer and author(s) with different levels of author blinding. Double-blind arguably reduces reviewer bias, but depending on the field and subject matter, once an author is recognizable, double-blinding doesn’t truly mask them.


  • Sumocat@lemmy.worldtoFunny@sh.itjust.worksCatch 22
    link
    fedilink
    English
    arrow-up
    9
    ·
    11 days ago

    Yes, it should look the same, and some journals go as far as redacting the references on the review copy entirely, so they all look exactly the same. That said, if an author is prestigious enough to be known, they need to do more than that to mask their identity. Writing styles and subject matter can give away an author’s identify even if blinded.


  • Sumocat@lemmy.worldtoFunny@sh.itjust.worksCatch 22
    link
    fedilink
    English
    arrow-up
    71
    ·
    12 days ago

    Double-blind review masks the author’s identity, including self-citations that would identify the author. The author may have done this too effectively, and/or the reviewer was not as familiar with the author’s work as the critique would imply.










  • His job is U.S. Senator, which he holds because he received the most votes from the state of New York. “Senate Minority Leader” is a position he holds because no one else wants it. It’s not a Constitutional position, like Speaker of the House or President of the Senate, and the U.S. Senate is a house of equals. Being “minority leader”bestows no added power, only responsibility for representing his party when negotiating with the other party. If another Senate Democrat wants to be responsible for negotiating with a senile man-child, they can call for a vote whenever the minority caucus meets.



  • You skipped right past the paragraph before that one describing the adult study that needs to succeed prior to the start of the child study.

    Now, scientists will see just how similar, because humans are undergoing a similar trial. Lasting 11 months, this study focuses on 30 males between the ages of 30 and 64—each missing at least one tooth. The drug will be administered intravenously to prove its effectiveness and safety, and luckily, no side effects have been reported in previous animal studies.